

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

20 MIN 10 100 100				_
		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
APPLICATION NO.	FILING DATE		9926-003-999	5583
09/536,552	03/28/2000 Andrew L. Mason		,,, 2 0 000 00	
20303	7590 04/12/2002		EXAMINER	
1155 AVENU	D EDMONDS E OF THE AMERICAS	EPPS		ANET L
NEW YORK,	NY 100362711		ART UNIT	PAPER NUMBER
			1635 DATE MAILED: 04/12/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
• 7	09/536,552	MASON ET AL.				
Advisory Action	Examiner	Art Unit				
en e	Janet I Enns. Ph.D.	1635				
The MAILING DATE of this communication app	pears on the cover sheet with the	correspondence address				
THE REPLY FILED FAILS TO PLACE THIS AP Therefore, further action by the applicant is required to final rejection under 37 CFR 1.113 may only be either: condition for allowance; (2) a timely filed Notice of App (NCF) in compliance with 37 CFR 1.114.	PLICATION IN CONDITION FOR avoid abandonment of this app	ok ALLOWANTOE: blication. A proper reply to a				
months from the mailing date of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this vevent, however, will the statutory period for reply expire later ONLY CHECK THIS BOX WHEN THE FIRST REPLY WA 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The have been filed is the date for purposes of determining the period of ext 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shorter (b) above, if checked. Any reply received by the Office later than three earned patent term adjustment. See 37 CFR 1.704(b).	than SIX MONTHS from the mailing data SFILED WITHIN TWO MONTHS OF date on which the petition under 37 CFR tension and the corresponding amount of ned statutory period for reply originally semonths after the mailing date of the final statutory.	R 1.136(a) and the appropriate extension fee if the fee. The appropriate extension fee under it in the final Office action; or (2) as set forth in rejection, even if timely filed, may reduce any within the period set forth in				
37 CFR 1.192(a), or any extension thereof (a)						
2. ☐ The proposed amendment(s) with not be officered as (a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);						
(a) ☑ they raise new issue of new matter (see Note below); (b) ☐ they raise the issue of new matter (see Note below);						
(b) ☐ they raise the issue of new matter (see Note below); (c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the						
issues for appeal; and/or						
issues for appeal; and/or (d) \(\square\) they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: See Continuation Sheet.						
3. Applicant's reply has overcome the following rejection(s):						
3. Applicant's reply has overcome the value of the second discovers discovers the second discovers discovers discovers discovers the second discovers discov						
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, of o) ☐ because: application in condition for allowance because: 6. ☐ The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly						
raised by the Examiner in the final rejection. 7.⊠ For purposes of Appeal, the proposed amendment(s) a)⊠ will not be entered or b)□ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: Claim(s) objected to: 2, remains objected for the Claim(s) rejected: 1 and 3-10 remain rejected: Claim(s) withdrawn from consideration: 8. The proposed drawing correction filed on 9. Note the attached Information Disclosure St	is a) approved or b) □	disapproved by the Examiner.				
10. Other:						

U.S. Patent and Trademark Office

.. Continuation Sheet (PTO-303) 09/536,552

Application No.

Continuation of 2. NOTE: Applicants have amended claims claims 1, 3, 4 and 7 to recite wherein the PSC retroviral nucleic acid molecule comprises SEQ ID NOS: 1-7, or a fragment or an allelic variant thereof. Applicant's amendment would raise new issues under 35 USC 112, first paragraph, for lack of written description of the claimed fragments and allelic variants of the sequences according SEQ ID NOS: 1-7. Additionally Applicants have amended claim 1 to recite wherein the disorder is selected from PSC, Autoimmune Hepatitis, Crohn's disease, cryptogenic cirrhosis or ulcerative colitis. The addition of the term "cryptogenic cirrhosis" in claim 1 would require further consideration and/or search. Applicant's arguments appear to be directed to the claims as amended. However, since the instant amendment has not been entered, these arguments are considered moot.